About TD2

TD2 is a biopharma service provider uniquely positioned to meet your development challenges. TD2 integrates world-class clinical and regulatory expertise with "-omic" science and provides unique drug development services aimed at minimizing the risk for clients in the Oncology drug development industry. Our platform, referred to as "De-Risk", is a comprehensive, multi-faceted solution intended to shorten development cycles for anti-cancer agents and improve their success rates.

De-Risk: Integrating genomics, informatics, preclinical and clinical innovations from bench to bedside serving the BioPharma industry

Reducing the Risk in Cancer Drug Development
  • Targeted trial designs for drug candidates
  • Execution of trials "enriched" with the right patients
  • Rapid determination of drug registration pathways
The De-Risk platform integrates a myriad of cutting edge preclinical, clinical, regulatory, and project management tools focused on rapid approval of anticancer agents. The heart of De-Risk is TD2's Oncologists and Managers; specifically, their ability to integrate and translate extreme clinical insight with scientific "mechanism-of-action" information directly into the design and execution of clinical trials. De-Risk helps define and exploit the "context" of a given cancer drug's effectiveness to provide value to clients at every stage of the drug development process.